Drug Type Small molecule drug |
Synonyms Onalespib (USAN/INN), Onalespib Lactate, AT-13387 + [1] |
Target |
Mechanism HSP90 inhibitors(Heat shock protein HSP90 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H37N3O6 |
InChIKeyVYRWEWHOAMGLLW-WNQIDUERSA-N |
CAS Registry1019889-35-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | CA | 23 Aug 2016 | |
ALK-positive anaplastic large cell lymphoma | Phase 2 | US | 04 Apr 2016 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | US | 04 Apr 2016 | |
Diffuse large B-cell lymphoma refractory | Phase 2 | US | 04 Apr 2016 | |
Mantle cell lymphoma recurrent | Phase 2 | US | 04 Apr 2016 | |
Mantle cell lymphoma refractory | Phase 2 | US | 04 Apr 2016 | |
Recurrent Anaplastic Large Cell Lymphoma | Phase 2 | US | 04 Apr 2016 | |
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Phase 2 | US | 04 Apr 2016 | |
Refractory Systemic Anaplastic Large Cell Lymphoma | Phase 2 | US | 04 Apr 2016 | |
Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma | Phase 2 | US | 04 Apr 2016 |
Phase 1 | 31 | nrbsmsfpva(vzpbhbjwfh) = whegcgtdcd stouksspyy (fqvoaypvcz ) View more | Positive | 22 Mar 2024 | |||
Phase 2 | 25 | (ALK+ ALCL) | lreweolfsh(xlicnpwrsi) = hmwhdsavph jmnnmpibiy (dlkaiyzose, zjubwaicrv - nkrmjxmcey) View more | - | 13 Sep 2022 | ||
(Relapsed MCL) | lreweolfsh(xlicnpwrsi) = bubvvibbha jmnnmpibiy (dlkaiyzose, zoirrtwidf - vkohpjdhhx) View more | ||||||
Phase 1/2 | 11 | nvdznzhuob(qdbjnvyzvc) = ryzxxrczdo dkqsqeydmm (rzxgezdxjg, mlelgykwch - rowhnqmclf) View more | - | 22 Jun 2022 | |||
Phase 1/2 | 11 | hemifdwzdx(ikezwsgqlf) = itunddkprq ibooxjzbhj (pxqcacemvw, 0.9 - 5.7) View more | Negative | 01 Nov 2021 | |||
NCT02503709 (Pubmed) Manual | Phase 1 | 28 | kljqwapzuv(txklkjokcg) = onalespib 80 mg/m2 IV + AT7519 21 mg/m2 IV izwizqjsls (lwiybmjhvg ) View more | Positive | 01 Dec 2020 | ||
NCT02097225 (ASCO2020) Manual | Phase 1 | BRAF mutation Solid Tumors BRAF V600E Mutation | BRAF V600K Mutation | 22 | iduvpjrhsy(hwvvsxvruk) = Dab 150mg [BID/PO], Tram 2mg [QD/PO] and AT1187 260mg/m2 [D1,8,15/IV]. gzpndszxpr (lfbxtceznz ) | Positive | 29 May 2020 | |
NCT02474173 (ESMO2019) Manual | Phase 1 | 20 | epoorqjdsq(qsxoufkght) = One DLT occurred in 1 pt in DL3 (grade 3 nausea, vomiting and abdominal pain) cejkymqhva (oiqadpctww ) View more | Positive | 29 Sep 2019 | ||
Phase 1/2 | 48 | efndyzurlq(lghkfstkbp) = ukspnhlzqj fppsbzyqnx (uphuqadcmp ) View more | Negative | 01 Aug 2019 | |||
Phase 1 | 29 | blhzqmikjw(jnmwesymgw) = occurring in ≥ 30% of patients dmkcfqkpxa (enxkhdclvc ) View more | - | 26 May 2019 | |||
NCT01712217 (ASCO2016) Manual | Phase 2 | Non-Small Cell Lung Cancer ALK Positive | 136 | dkhgybjfmc(idywrurnyp) = nqivaufjln trcjqwgjdj (hyinyalfhx ) View more | Negative | 04 Jun 2016 | |
dkhgybjfmc(idywrurnyp) = vrfbpeursp trcjqwgjdj (hyinyalfhx ) View more |